NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
36.53
-0.47 (-1.27%)
Nov 4, 2025, 4:00 PM EST - Market closed
NAMS Revenue
NewAmsterdam Pharma Company had revenue of $19.15M in the quarter ending June 30, 2025, with 740.06% growth. This brings the company's revenue in the last twelve months to $64.01M, up 762.15% year-over-year. In the year 2024, NewAmsterdam Pharma Company had annual revenue of $45.56M with 223.37% growth.
Revenue (ttm)
$64.01M
Revenue Growth
+762.15%
P/S Ratio
61.20
Revenue / Employee
$941,265
Employees
68
Market Cap
4.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 45.56M | 31.47M | 223.37% |
| Dec 31, 2023 | 14.09M | -88.60M | -86.28% |
| Dec 31, 2022 | 102.69M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
NAMS News
- 5 days ago - NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November - GlobeNewsWire
- 5 weeks ago - NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum - GlobeNewsWire
- 2 months ago - NewAmsterdam Pharma Company N.V. (NAMS) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 2 months ago - NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September - GlobeNewsWire
- 2 months ago - Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site - PRNewsWire
- 2 months ago - NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib - GlobeNewsWire
- 3 months ago - NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results - GlobeNewsWire
- 3 months ago - NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer's Disease Biomarkers at AAIC 2025 - GlobeNewsWire